Article

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

2024-05-29

Abstract excerpt

<title>Abstract</title> <p>Background With the approval of disease-modifying treatments (DMTs) for early Alzheimer’s disease (AD), there is an increased need for efficient and non-invasive detection methods for cerebral amyloid-β (Aβ) pathology. Current methods, including positron emission tomography (PET) and cerebrospinal fluid (CSF) analysis, are costly and invasive methods that may limit access to new treatm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9b0ff373-596a-535c-bf53-809c5192ba7e
DOI: 10.21203/rs.3.rs-3755419/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseDOI 10.21203/rs.3.rs-3755419/v1Read

Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity Read

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity Read

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity Read

Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathologySemantic proximity Read

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity Read

CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity Read

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity Read

Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinicsSemantic proximity Read

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measuresSemantic proximity Read

Analytical and Clinical Validation of a High Accuracy Fully Automated Digital Immunoassay for Plasma Phospho-Tau 217 for Clinical Use in Detecting Amyloid PathologySemantic proximity Read

Performance of plasma p‐tau217 and NfL in an unselected memory clinic settingSemantic proximity Read